Drug Database
IM

immunoglobulin (Bivigam)

✓ Approved

ADMA Biologics, Inc. · 多克隆抗体 · 多克隆抗体

什么是 immunoglobulin?

immunoglobulin 是一种多克隆抗体,由ADMA Biologics, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)。

药物档案

商品名Bivigam
公司ADMA Biologics, Inc.
药物类别多克隆抗体, 抗体
给药途径Injectable (Others), Intravenous (IV)
状态Approved

治疗适应症

immunoglobulin 针对 5 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
Congenital, familial and genetic disordersCombined immunodeficiency✓ Approved
Congenital, familial and genetic disordersWiskott-Aldrich syndrome✓ Approved
Immune system disordersSelective IgG subclass deficiency✓ Approved
Congenital, familial and genetic disordersBruton's agammaglobulinaemia✓ Approved
Immune system disordersImmunodeficiency✓ Approved

相关研究文献

PubMedHaematologica2026-11-19

Comment on: "Effect of intravenous immunoglobulin on infections in multiple myeloma patients receiving daratumumab".

Rago Angela A, Zomparelli Marco M, Di Toritto Tommaso Caravita TC

PMID 43053702
阅读全文 →
PubMedClinical pediatrics2026-11-19

Patterns and Factors Associated With Coronary Artery Involvement in Kawasaki Disease: Experience From Southern Tunisia.

Elleuch Amal A, Elleuch Imen I, Ben Halima Asma A, Gargouri Rania R et al.

Kawasaki disease (KD) is a paediatric vasculitis associated with coronary complications. We aimed to describe clinical and echocardiographic characteristics and factors associated with coronary involvement. This retrospective, single-centre study included 70 children over 18 years (2007-2024). Univariate analyses assessed clinical and laboratory associations. The mean age was 55.4 ± 32.8 months; 61.7% were younger than 5 years. Coronary involvement occurred in 32/70 (45.7%), including dilation in 25 (35.7%), wall thickening in 7 (10.0%) and aneurysms in 3 (4.3%). Lesions regressed in 27/32 (84.4%). Significant associations included cheilitis, rash, cervical lymphadenopathy, cough, rhinorrhoea, leucocytosis, lymphocytosis, lower mean corpuscular volume, higher mean corpuscular haemoglobin concentration, thrombocytosis and elevated alanine aminotransferase. These unadjusted associations do not establish independent predictors. Early diagnosis, intravenous immunoglobulin and aspirin remain essential. Systematic echocardiographic assessment, structured follow-up and larger multicentre studies are needed to improve coronary risk stratification and long-term outcomes in children with KD.

PMID 43052696
阅读全文 →
PubMedBMC neurology2026-11-19

Dramatic clinical and radiological improvement in acute hemorrhagic leukoencephalitis: a case report.

Alasow Mohamed Osman Dahir MOD, Osman Ahmed Adam AA, Hirsi Ibrahim Mohamed IM, Ismail Farah Abdullahi FA et al.

Acute hemorrhagic leukoencephalitis (AHLE) is a rare, fulminant inflammatory demyelinating disorder considered a severe variant of acute disseminated encephalomyelitis and is associated with high morbidity and mortality, particularly in children. Early diagnosis remains challenging due to its rarity and overlap with other acute encephalopathies. We present the case of a previously healthy young 15-year-old Somali girl who exhibited acute headache, altered mental status, and cerebellar ataxia. Initial non-contrast computed tomography revealed diffuse cerebral edema with bilateral thalamic hemorrhagic involvement. Subsequent magnetic resonance imaging demonstrated extensive bilateral cerebral and cerebellar lesions with symmetrical involvement of the thalami and hippocampi, showing hemorrhagic transformation without contrast enhancement, findings consistent with acute hemorrhagic leukoencephalitis. MR venography was normal. The patient was treated with high-dose intravenous methylprednisolone and intravenous immunoglobulin, along with supportive care. A follow-up MRI done two weeks later showed that the lesions had gotten much better. The patient made a full neurological recovery and was sent to their home in excellent health. This case underscores the essential role of early clinical suspicion and distinctive MRI findings in diagnosing acute hemorrhagic leukoencephalitis. Starting aggressive immunomodulatory therapy right away can lead to huge improvements in both clinical and radiological outcomes, even in extreme cases and places with few resources. Heightened awareness of this uncommon condition is crucial for enhancing outcomes and decreasing related mortality.

PMID 43052797
阅读全文 →
PubMedJournal of medical case reports2026-11-19

Progressive multifocal leukoencephalopathy in a 15-year-old boy with X-linked hyper-IgM syndrome: a case report.

Delavari Saeedeh S, Pourvali Ali A, Akbari Mehran M, Vajdian Shiva S et al.

Progressive multifocal leukoencephalopathy (PML) is a rare and potentially fatal infection caused by JC polyomavirus, primarily affecting individuals with impaired cellular immunity. We report a 15-year-old boy with genetically confirmed X-linked hyper-IgM syndrome due to a pathogenic CD40LG variant. Despite regular intravenous immunoglobulin replacement therapy and antimicrobial prophylaxis, he developed concurrent Pneumocystis jirovecii pneumonia and COVID-19. Approximately 2 months after recovery from the pulmonary infections, he developed progressive visual impairment, diplopia, impaired concentration, and mild generalized weakness. Brain magnetic resonance imaging revealed extensive bilateral temporo-parieto-occipital white-matter lesions. Cerebrospinal fluid polymerase chain reaction was positive for JC polyomavirus DNA, confirming the diagnosis of PML; HIV testing was negative. In the absence of an established antiviral therapy, a single intravenous dose of pembrolizumab (80 mg) was administered as an experimental immune-based intervention. Three weeks later, the patient developed rapidly progressive generalized muscle weakness and respiratory failure requiring intensive care and mechanical ventilation. Despite intensive supportive treatment, he subsequently died. The precise cause of this deterioration could not be conclusively established, and a multifactorial process involving progression of PML and treatment-related or critical-illness complications could not be excluded. PML should be considered in patients with X-linked hyper-IgM syndrome who develop new neurological manifestations. Pembrolizumab remains an experimental intervention in this setting, with uncertain efficacy and safety in primary immunodeficiency.

PMID 43053104
阅读全文 →
PubMedBMC public health2026-11-19

Post-pandemic SARS-CoV-2 seroprevalence and population immunity in Conakry, Guinea, 2024.

Kadio Kadio Jean Jacques Olivier KJJO, Diallo Haby H, Gnimadi Thibaut Armel Chérif TAC, Soumah Abdoul Karim AK et al.

Since May 2023, COVID-19 is no longer a Public Health Emergency of International Concern. However, it remains an infection that requires monitoring, especially in the post-emergency context where testing and preventative measures have been abandoned by the population. The objective of this study was therefore to measure the seroprevalence of antibodies against SARS-CoV-2 in Conakry in the post-health emergency period and to identify the associated factors. In January 2024, we conducted a population-based, age-stratified seroprevalence survey in Conakry. We collected demographic and epidemiological information, as well as dried blood spot samples, and tested them for immunoglobulin G (IgG) antibodies to SARS-CoV-2 recombinant nucleocapsid and spike proteins using Luminex technology. Overall, 1018 individuals with a median age of 18 years (IQR: 10-37 years) from 180 households participated in the survey. The overall weighted and age-standardized SARS-CoV-2 IgG seroprevalence against spike and nucleocapsid proteins was 88.9% (95% CI: 80.8-93.9). People with secondary education (AOR = 4.10, 95% CI: 1.46-11.51) and those who had been vaccinated (AOR = 2.53, 95% CI: 1.26-5.10) were significantly more likely to have SARS-CoV-2 antibodies. High SARS-CoV-2 seroprevalence in Conakry indicates widespread community exposure through infection and/or vaccination. Secondary education and vaccination were associated with antibody positivity. Despite strong population immunity, continued surveillance, improved vaccine access, and strengthened public health communication remain essential to address ongoing viral circulation and potential waning immunity in Guinea.

PMID 43052926
阅读全文 →
PubMedEuropean journal of pediatrics2026-11-19

KAWACALP study: the utility of serum calprotectin as a prognostic biomarker in Kawasaki disease.

Mercader Rodríguez Beatriz B, Avilés Plaza Francisco V FV, Sorlí García Moisés M, Fernández Cooke Elisa E et al.

To assess if serum calprotectin (sCP) can be used as a predictor of resistance to intravenous immunoglobulin treatment (IVIG) and coronary artery aneurysms (CAA) in Kawasaki disease (KD). A multicenter, observational, cohort study was conducted prospectively between September 2018 and February 2023. sCP was analyzed at four points in the evolution of KD in 74 patients from four Spanish hospitals. The sCP and other clinical and analytical values were compared between groups: IVIG responders or sensitive KD patients (SKD) versus IVIG nonresponders or refractory KD patients (RKD), and KD patients with CAA versus those without CAA. In refractory KD patients and in those who developed CAA, sCP was higher at the moment of diagnosis and remained elevated after treatment with IVIG, unlike what happened in sensitive KD patients and in those without CAA. A post-treatment sCP level ≥ 14.09 μg/ml predicted RKD with Sn 75% and Sp 72.97% (AUC 0.75). A pre-treatment sCP cutoff of ≥ 21.49 μg/ml predicted CAA with Sn:100% and Sp 71.05% (AUC 0.86). A post-treatment sCP value ≥ 14.76 μg/ml predicted CAA with S 71.43% and Sp 76.32% (AUC 0.74). Serum CP at the time of diagnosis ≥ 21.49 μg/ml has a sensitivity of 100% to detect CAA. Therefore, if these results are confirmed in larger studies, sCP may be used as a prognostic biomarker in patients with Kawasaki disease, to detect early patients with a higher probability of CAA occurrence, guide treatment decisions and ultimately reduce cardiac complications. • At present, no validated biomarkers allow early identification of IVIG resistance or predict coronary involvement in KD patients. • High serum calprotectin level at the diagnosis of KD and persistently elevated levels after IVIG treatment may identify patients at risk for IVIG resistance and coronary complications.

PMID 43052573
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多immunoglobulin